Skip to main content

Correction to: Surfen and oxalyl surfen decrease tau hyperphosphorylation and mitigate neuron deficits in vivo in a zebrafish model of tauopathy

The Original Article was published on 16 March 2018

Correction to: Transl Neurodegener 7, 6 (2018)

https://doi.org/10.1186/s40035-018-0111-2

Following the publication of the original article [1], it was noted that due to a typesetting error several lines are mistakenly added in the Fig. 1 and they should be deleted.

Fig. 1
figure1

Surfen and oxalyl surfen are well tolerated by Tg [HuC::hTauP301L; DsRed] embryos. a Chemical structure of Surfen (1,3-bis(4-amino-2-methylquinolin-6-yl) urea), oxalyl surfen (N1,N2- bis(4-amino-2-methylquinolin-6-yl)oxalamide) and hemisurfen (1-(4-amino-2-methylquinolin-6- yl)urea). b Phenotypic analysis of 72 hpf wild-type (WT) and Tg [HuC::hTauP301L; DsRed] (hTauP301L) embryos incubated for 2 days in E3 medium containing 1% DMSO (hTauP301L + 1% DMSO), 80 mM LiCl (hTauP301L + LiCl), 3 μM surfen (hTauP301L + surfen), 2 μM oxalyl surfen (hTauP301L + oxalyl surfen) or 3 μM hemisurfen (hTauP301L + hemisurfen), showed that embryonic development is not impaired by the treatments. Magnification × 40. c Survival rate of 72 hpf wild-type (WT) and Tg [HuC::hTauP301L; DsRed] (hTauP301L) embryos incubated for 2 days in E3 medium containing 1% DMSO (hTauP301L + 1% DMSO), 80 mM LiCl (hTauP301L + LiCl), 3 μM surfen (hTauP301L + surfen), 2 μM oxalyl surfen (hTauP301L + oxalyl surfen), or 3 μM hemisurfen (hTauP301L + hemisurfen), demonstrated that embryonic mortality was not significantly increased by treatments (n = 250, P > 0.05, Student’s t test)

The correct figure has been included in this correction, and the original article has been corrected.

Reference

  1. 1.

    Alavi Naini SM, et al. Surfen and oxalyl surfen decrease tau hyperphosphorylation and mitigate neuron deficits in vivo in a zebrafish model of tauopathy. Transl Neurodegener. 2018;7:6. https://doi.org/10.1186/s40035-018-0111-2.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Nadia Soussi-Yanicostas.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Naini, S.M.A., Yanicostas, C., Hassan-Abdi, R. et al. Correction to: Surfen and oxalyl surfen decrease tau hyperphosphorylation and mitigate neuron deficits in vivo in a zebrafish model of tauopathy. Transl Neurodegener 9, 45 (2020). https://doi.org/10.1186/s40035-020-00220-3

Download citation

\